Significant interaction between testosterone recovery (TR) and biochemical progression-free survival (BPFS) in intermediate and high-risk patients with prostate cancer treated with radiation therapy (RT) and androgen deprivation therapy (ADT)

被引：0
|
作者：
Shasha, D.
Nabhani, T.
Rauth, S. J.
Salant, R.
Harrison, L. B.
机构：
[1] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, New York, NY 10003 USA
[2] SUNY Hlth Sci Ctr, Dept Radiat Oncol, Brooklyn, NY USA
[3] Beth Israel Deaconess Med Ctr, Dept Urol, New York, NY 10003 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 07期
关键词：
D O I：
10.1200/jco.2011.29.7_suppl.202
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
202
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Androgen deprivation therapy use and risk of death in men treated with high-dose radiation for intermediate-risk prostate cancer
    Keane, Florence K.
    D'Amico, Anthony V.
    CANCER, 2016, 122 (15) : 2296 - 2298
  • [42] Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer
    Ghadjar, Pirus
    Boehmer, Dirk
    Hoecht, Stefan
    Sedlmayer, Felix
    Wiegel, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15) : 1746 - +
  • [43] Is Androgen Deprivation Therapy Necessary in Intermediate Risk Prostate Cancer Patients Treated in the Dose Escalation Era?
    Castle, K. O.
    Hoffman, K. E.
    Levy, L. B.
    Lee, A. K.
    Choi, S.
    Nguyen, Q. N.
    Frank, S. J.
    Pugh, T.
    McGuire, S. E.
    Kuban, D. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S40 - S41
  • [44] Testosterone replacement therapy (TRT) in patients with locoregional prostate cancer (LPC) treated with prior androgen deprivation therapy (ADT): A single center review.
    Aglan, Mostafa
    Khadke, Sumanth
    Connell, Brendan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision
    Castro Mendez, Lucas
    Martell, Kevin
    Crook, Juanita M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3820 - +
  • [46] Preoperative Androgen Deprivation Therapy for Localized Prostate Cancer: Delayed Biochemical Recurrence in High-Risk Disease
    Pal, Sumanta K.
    Ruel, Nora
    Vogelzang, Nicholas
    Chang, Mark
    Wilson, Timothy G.
    Jones, Jeremy O.
    Yuh, Bertram
    CLINICAL GENITOURINARY CANCER, 2014, 12 (03) : 149 - 154
  • [47] Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy
    Utsumi, Takanobu
    Suzuki, Hiroyoshi
    Ishikawa, Hitoshi
    Wakatsuki, Masaru
    Okonogi, Noriyuki
    Harada, Masaoki
    Ichikawa, Tomohiko
    Akakura, Koichiro
    Murakami, Yoshitaka
    Tsuji, Hiroshi
    Yamada, Shigeru
    CURRENT ONCOLOGY, 2023, 30 (10) : 8815 - 8825
  • [48] Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy
    Yang, David D.
    Muralidhar, Vinayak
    Mahal, Brandon A.
    Nguyen, Paul L.
    Devlin, Phillip M.
    King, Martin T.
    Orio, Peter F., III
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (01): : 53 - 58
  • [49] CONTINUED BENEFIT TO ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER PATIENTS TREATED WITH DOSE-ESCALATED RADIATION THERAPY ACROSS MULTIPLE DEFINITIONS OF HIGH-RISK DISEASE
    Stenmark, Matthew H.
    Blas, Kevin
    Halverson, Schuyler
    Sandler, Howard M.
    Feng, Felix Y.
    Hamstra, Daniel A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04): : E335 - E344
  • [50] Impact of therapy on gene expression in high-risk prostate cancer (PCA) treated with neoadjuvant docetaxel and androgen deprivation therapy
    Beltran, Himisha
    Wyatt, Alexander
    Chedgy, Edmund
    Fazli, Ladan
    Sboner, Andrea
    Halabi, Susan
    Gleave, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345